Nonobstructive hypertrophic cardiomyopathy (HCM) is a condition in which a portion of the heart becomes thickened. This reduces the heart’s ability to pump blood effectively, which leads to a reduced capacity for physical activity among patients. This study aims to evaluate the effect of trimetazidine dihydrochloride, a drug for angina, on exercise capacity in patients with nonobstructive HCM.

This randomized, double-blind, placebo-controlled trial included a total of 49 participants aged 24 to 74 years with a maximum left ventricular outflow tract gradient 50 mg Hg or lower. The participants were randomly assigned in a 1:1 ratio to receive trimetazidine, 20 mg, 3 times a day (n=26) or placebo (n=24) for three months. The primary outcome of the study was peak oxygen consumption during upright bicycle ergometry.

The findings suggested that trimetazidine therapy was not associated with an improvement in exercise capacity. The participants in the trimetazidine group walked 38.4 m less than those in the placebo group. Further adjustment of baseline values indicated that peak oxygen consumption was 1.35 mL/kg per minute lower in the trimetazidine group.

The research concluded that in patients with nonobstructive HCM, trimetazidine dihydrochloride therapy did not improve exercise capacity.